Objective: To characterize and further compare the immune cell populations of the tumor microenvironment (TME) in both clear cell and papillary renal cell carcinoma (RCC) using heavy metal-labeled ...

Real-world (RW) treatment (tx) patterns and clinical outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) in the US community setting. OCTOPUS: A retrospective, multicenter study of ...

Ferring Pharmaceuticals announced today three abstracts featuring ADSTILADRIN® (nadofaragene firadenovec-vncg) will be presented at the 2025 American Society of Clinical Oncologists Genitourinary ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

ImmunityBio (IBRX) announced the Medicines and Healthcare products Regulatory Agency has validated and accepted the marketing authorization ...

A biopsy reveals squamous cell carcinoma (SCC) in situ. What should be the next steps in the patient's evaluation and management? After the initial consultation, the patient's biopsy specimen was ...

with carcinoma in situ (CIS), with or without papillary tumours. Bladder cancer is one of the more common forms of cancer. According to the Centers for Disease Control and Prevention, about 57,000 ...

with carcinoma in situ (CIS) with or without papillary tumors, ImmunityBio announced in a news release. 1 The MHRA will now review the application for potential approval in the United Kingdom. “MHRA’s ...

Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe in patients with ...

with carcinoma in situ (CIS), with or without papillary tu CULVER CITY, Calif., January 15, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant ...